EA201391492A1 - Соединения на основе микрорнк и способы модулирования активности mir-21 - Google Patents

Соединения на основе микрорнк и способы модулирования активности mir-21

Info

Publication number
EA201391492A1
EA201391492A1 EA201391492A EA201391492A EA201391492A1 EA 201391492 A1 EA201391492 A1 EA 201391492A1 EA 201391492 A EA201391492 A EA 201391492A EA 201391492 A EA201391492 A EA 201391492A EA 201391492 A1 EA201391492 A1 EA 201391492A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mir
methods
microrna
connections
basis
Prior art date
Application number
EA201391492A
Other languages
English (en)
Other versions
EA025894B1 (ru
Inventor
Балкришен Бхат
Original Assignee
Регулус Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Регулус Терапьютикс Инк. filed Critical Регулус Терапьютикс Инк.
Publication of EA201391492A1 publication Critical patent/EA201391492A1/ru
Publication of EA025894B1 publication Critical patent/EA025894B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification

Abstract

В данном документе описаны композиции и способы для ингибирования активности miR-21. Композиции имеют определенные паттерны модификаций нуклеозидов, позволяющие получать сильные ингибиторы активности miR-21. Композиции можно применять для ингибирования miR-21, а также для лечения заболеваний, ассоциированных с аномальной экспрессией miR-21, таких как фиброз и рак.
EA201391492A 2011-04-25 2012-04-25 Соединения на основе микрорнк и способы модулирования активности mir-21 EA025894B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478767P 2011-04-25 2011-04-25
US201161565779P 2011-12-01 2011-12-01
PCT/US2012/034880 WO2012148952A1 (en) 2011-04-25 2012-04-25 Microrna compounds and methods for modulating mir-21 activity

Publications (2)

Publication Number Publication Date
EA201391492A1 true EA201391492A1 (ru) 2014-04-30
EA025894B1 EA025894B1 (ru) 2017-02-28

Family

ID=46025979

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391492A EA025894B1 (ru) 2011-04-25 2012-04-25 Соединения на основе микрорнк и способы модулирования активности mir-21

Country Status (30)

Country Link
US (7) US20120270928A1 (ru)
EP (3) EP3211082B1 (ru)
JP (2) JP6320292B2 (ru)
KR (2) KR20190063482A (ru)
CN (3) CN113249381A (ru)
AU (4) AU2012249851B2 (ru)
BR (1) BR112013027187A2 (ru)
CA (2) CA2833615C (ru)
CL (1) CL2013003105A1 (ru)
CO (1) CO6821889A2 (ru)
CY (1) CY1120304T1 (ru)
DK (2) DK3211082T3 (ru)
EA (1) EA025894B1 (ru)
ES (2) ES2621863T3 (ru)
HK (1) HK1243130A1 (ru)
HR (2) HRP20170557T2 (ru)
HU (2) HUE031595T2 (ru)
IL (3) IL229032B (ru)
LT (2) LT3211082T (ru)
MX (5) MX2013012452A (ru)
MY (2) MY187685A (ru)
NZ (1) NZ717921A (ru)
PL (2) PL3211082T3 (ru)
PT (2) PT2702155T (ru)
RS (1) RS61775B1 (ru)
SG (1) SG194636A1 (ru)
SI (2) SI2702155T1 (ru)
TW (2) TWI698445B (ru)
UA (1) UA115652C2 (ru)
WO (1) WO2012148952A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
CA2833615C (en) 2011-04-25 2022-08-30 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
US9193971B2 (en) * 2012-04-10 2015-11-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for the treatment of nonalcoholic steatohepatitis
IN2014DN09134A (ru) 2012-04-25 2015-05-22 Regulus Therapeutics Inc
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
CN117126846A (zh) 2012-11-15 2023-11-28 罗氏创新中心哥本哈根有限公司 寡核苷酸缀合物
JP2016518842A (ja) * 2013-05-01 2016-06-30 レグルス セラピューティクス インコーポレイテッド マイクロＲＮＡ化合物およびｍｉＲ−１２２をモジュレートする方法
EP3060664B1 (en) * 2013-10-25 2021-07-07 Sanofi Microrna compounds and methods for modulating mir-21 activity
KR101625755B1 (ko) 2013-11-18 2016-05-30 울산대학교 산학협력단 ｍｉＲＮＡ 스폰지 및 이의 용도
CA2935426C (en) * 2014-01-30 2023-07-25 F. Hoffmann-La Roche Ag Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
CN105734127A (zh) * 2016-02-29 2016-07-06 上海中医药大学 miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途
WO2017187426A1 (en) * 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
WO2019060771A2 (en) 2017-09-22 2019-03-28 University Of Washington IN SITU COMBINATORY MARKING OF CELLULAR MOLECULES
CN108148911B (zh) * 2018-03-02 2019-11-05 广州医科大学附属第二医院 miR-582在制备***癌骨转移的诊断、预后试剂盒及药物中的应用
CN110747266A (zh) * 2018-07-23 2020-02-04 深圳先进技术研究院 miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用
CN109880907A (zh) * 2019-03-26 2019-06-14 中国人民解放军第八一医院 一种肝癌细胞侵袭转移的分子机制研究方法
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2022165092A1 (en) * 2021-01-29 2022-08-04 Angion Biomedica Corp. Methods for treatment of fibrotic diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008817A1 (en) * 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
EP2386637B1 (en) 2001-09-28 2018-05-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
JP4731324B2 (ja) 2003-08-28 2011-07-20 武 今西 Ｎ−ｏ結合性架橋構造型新規人工核酸
CA2576233C (en) 2004-08-10 2016-03-15 Alnylam Pharmaceuticals, Inc. Conjugate comprising an antagomir and a ligand
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US20070099196A1 (en) 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
EP2338992A3 (en) 2005-08-29 2011-10-12 Regulus Therapeutics, Inc Antisense compounds having enhanced anti-microRNA activity
AU2007211082B2 (en) 2006-01-27 2012-09-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
DK2314594T3 (da) 2006-01-27 2014-10-27 Isis Pharmaceuticals Inc 6-modificerede bicykliske nukleinsyreanaloger
EP2261333B1 (en) * 2006-04-03 2016-03-30 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
JP5814505B2 (ja) 2006-04-03 2015-11-17 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
AU2007303205A1 (en) 2006-10-03 2008-04-10 Tekmira Pharmaceuticals Corporation Lipid containing formulations
EP2208798B1 (de) 2006-10-09 2013-08-07 Medizinische Hochschule Hannover MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen
WO2008073920A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
US8048998B2 (en) 2007-01-19 2011-11-01 Exiqon A/S Mediated cellular delivery of LNA oligonucleotides
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
US20100261175A1 (en) 2007-06-15 2010-10-14 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
EP2203559B1 (en) * 2007-10-04 2014-02-26 Stella ApS Combination treatment for the treatment of hepatitis c virus infection
CN101980712B (zh) * 2007-10-29 2015-02-18 雷古拉斯治疗公司 用于肝癌治疗的靶向微小rna
US20110257244A1 (en) 2008-01-18 2011-10-20 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
EP2096171A1 (en) * 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
JP2012518997A (ja) * 2009-02-26 2012-08-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 喫煙未経験者におけるマイクロｒｎａ、ならびに関連する材料および方法
EP2440566A4 (en) * 2009-06-08 2013-10-16 Miragen Therapeutics CHEMICAL MODIFICATION RULES FOR INHIBITORS AND MIMETICS OF MIRIK
WO2011126842A2 (en) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
CA2833615C (en) 2011-04-25 2022-08-30 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
IN2014DN09134A (ru) 2012-04-25 2015-05-22 Regulus Therapeutics Inc
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
CN104955950B (zh) 2012-09-26 2019-04-26 米尔克斯治疗学公司 具有改善的脱靶特征谱的寡核苷酸
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Also Published As

Publication number Publication date
US20180155719A1 (en) 2018-06-07
EP3211082A1 (en) 2017-08-30
EA025894B1 (ru) 2017-02-28
MY175336A (en) 2020-06-19
BR112013027187A2 (pt) 2017-06-06
IL229032A0 (en) 2013-12-31
HUE054129T2 (hu) 2021-08-30
AU2020201403A1 (en) 2020-03-12
CL2013003105A1 (es) 2014-08-01
CO6821889A2 (es) 2013-12-31
JP2014518619A (ja) 2014-08-07
ES2621863T9 (es) 2020-02-13
HRP20170557T1 (hr) 2017-06-16
US20120270928A1 (en) 2012-10-25
US9181547B2 (en) 2015-11-10
CA2833615C (en) 2022-08-30
CN103620035A (zh) 2014-03-05
TW201300404A (zh) 2013-01-01
AU2022203067A1 (en) 2022-05-26
NZ616748A (en) 2016-03-31
LT3211082T (lt) 2021-05-10
MX2013012452A (es) 2014-11-21
PL3211082T3 (pl) 2021-08-02
IL273381A (en) 2020-05-31
AU2017219156A1 (en) 2017-09-21
CN113151272A (zh) 2021-07-23
EP2702155B9 (en) 2020-01-01
HRP20210616T1 (hr) 2021-05-28
HRP20170557T2 (hr) 2020-02-21
TWI698445B (zh) 2020-07-11
US8912161B2 (en) 2014-12-16
AU2012249851A8 (en) 2013-11-14
WO2012148952A1 (en) 2012-11-01
PT2702155T (pt) 2017-04-03
US20200291400A1 (en) 2020-09-17
IL229032B (en) 2021-01-31
US9790496B2 (en) 2017-10-17
MX2022000212A (es) 2022-04-01
LT2702155T (lt) 2017-05-10
PT3211082T (pt) 2021-04-28
KR20140033062A (ko) 2014-03-17
DK2702155T3 (en) 2017-05-01
US20220098583A1 (en) 2022-03-31
EP3933040A1 (en) 2022-01-05
SI3211082T1 (sl) 2021-08-31
AU2017219156B2 (en) 2020-01-02
AU2012249851A1 (en) 2013-10-31
CN103620035B (zh) 2021-04-23
KR20190063482A (ko) 2019-06-07
EP3211082B1 (en) 2021-02-17
HK1243130A1 (zh) 2018-07-06
MX2019003090A (es) 2019-07-18
US20140107183A1 (en) 2014-04-17
US20160138016A1 (en) 2016-05-19
RS61775B1 (sr) 2021-05-31
JP6320292B2 (ja) 2018-05-09
KR102055172B1 (ko) 2020-01-23
DK3211082T3 (da) 2021-05-10
ES2621863T3 (es) 2017-07-05
CY1120304T1 (el) 2019-07-10
TW201811812A (zh) 2018-04-01
CN113249381A (zh) 2021-08-13
CA3165397A1 (en) 2012-11-01
ES2868950T3 (es) 2021-10-22
SG194636A1 (en) 2013-12-30
MX2022006595A (es) 2022-07-01
MX2019003089A (es) 2019-07-18
HUE031595T2 (en) 2017-07-28
AU2012249851B2 (en) 2017-06-08
NZ717921A (en) 2017-09-29
JP2018121646A (ja) 2018-08-09
EP2702155B1 (en) 2017-02-01
CA2833615A1 (en) 2012-11-01
US20140329887A1 (en) 2014-11-06
MY187685A (en) 2021-10-11
EP2702155A1 (en) 2014-03-05
SI2702155T1 (sl) 2017-07-31
UA115652C2 (uk) 2017-12-11
IL266529A (en) 2019-07-31
PL2702155T3 (pl) 2017-09-29
TWI607016B (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
EA201391492A1 (ru) Соединения на основе микрорнк и способы модулирования активности mir-21
EA201491953A1 (ru) СОЕДИНЕНИЯ НА ОСНОВЕ МИКРОРНК И СПОСОБЫ МОДУЛИРОВАНИЯ АКТИВНОСТИ miR-21
AU2018236800B2 (en) DNA-PK inhibitors
EA201890059A1 (ru) Ингибиторы hpk1 и способы их применения
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
EA201490042A1 (ru) Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
ECSP14013153A (es) Compuestos inhibidores de metaloenzimas
MX2013010170A (es) Moduladores heterociclicos de sintesis lipidica.
ECSP13012869A (es) Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos
EA201490545A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ С-Kit
PH12014502513A1 (en) Nampt inhibitors
MX2014013752A (es) Inhibidores de nampt.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201790032A1 (ru) Бициклически замещённые урацилы и их применение
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
EA201490643A1 (ru) Новые производные бетулиновой кислоты с противовирусной активностью
MX348311B (es) Inhibidores nampt.
EA201690844A1 (ru) Ингибиторы gsk-3
GB201312965D0 (en) Stem cell factor inhibitor
EA201390876A1 (ru) Соединения, ингибирующие металлоферменты
EA201590656A1 (ru) Азаиндолины
TN2014000401A1 (en) Microrna compounds and methods for modulating mir-21 activity

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM